Phase 4 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People who have been diagnosed with Stage 0 to Stage 3 hormone-receptor positive breast cancer, confirmed at MSKCC
- People who are able to complete study questionnaires in English or Spanish
- People who have finished their main breast cancer treatments (such as surgery, chemotherapy, or radiation therapy), or who are currently on ongoing maintenance treatment
- People who are currently taking an aromatase inhibitor, tamoxifen, or a similar type of medication (called a SERM)
- People who currently have no signs of active cancer
- People who are experiencing vaginal symptoms linked to low estrogen, such as vaginal dryness, pain during intercourse, or discomfort during a medical examination
- People whose vaginal symptom score reaches 4 or higher on a specific rating scale used in the study (confirm with trial site)
- People with no history of other cancers, apart from a common type of skin cancer called non-melanoma skin cancer
- People who are willing to sign a consent form showing they understand the study and agree to take part
Who may not be able to join:
- People who are not able to give informed consent
- People who have had vaginal bleeding with no known cause within the past 12 months
- People who are currently using hormone replacement therapy, either applied locally or taken throughout the body (a 4-week stop period may be required before the trial site can consider enrolment)
- People who are currently using external estrogen products or non-hormonal vaginal moisturisers (a 4-week stop period may be required before the trial site can consider enrolment)
- People who have a known allergy to any ingredient in the study treatment, a 10mg hyaluronic acid suppository
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shari Goldfarb, MD, Memorial Sloan Kettering Cancer Center
Phone: 646-888-5080
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Vaginal Assessment Scale from baseline to 8 weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.